Journal Home
Search for

Volume 66, Issue 2, Pages 191-195 (15 July 2009)


View previous. 19 of 20 View next.

Tumor Necrosis Factor Antagonism Normalizes Rapid Eye Movement Sleep in Alcohol Dependence

Michael R. IrwinaCorresponding Author Informationemail address, Richard Olmsteada, Edwin M. Valladaresa, Elizabeth Crabb Breena, Cindy L. Ehlersb

Received 24 July 2008; received in revised form 14 November 2008; accepted 4 December 2008. published online 30 January 2009.

Background

In alcohol dependence, markers of inflammation are associated with increases in rapid eye movement (REM) sleep, which is thought to be a prognostic indicator of alcohol relapse. This study was undertaken to test whether blockade of biologically active tumor necrosis factor-α (TNF-α) normalizes REM sleep in alcohol-dependent adults.

Methods

In a randomized, placebo-controlled, double-blind, crossover trial, 18 abstinent alcohol-dependent male adults received a single dose of etanercept (25 mg) versus placebo in a counterbalanced order. Polysomnographic sleep was measured at baseline and for 3 nights after the acute dose of etanercept or placebo.

Results

Compared with placebo, administration of etanercept produced significant decreases in the amount and percentage of REM sleep. Decreases in REM sleep were robust and approached low levels typically found in age-comparable control subjects. Individual differences in biologically active drug as indexed by circulating levels of soluble tumor necrosis factor receptor II negatively correlated with the percentage of REM sleep.

Conclusions

Pharmacologic neutralization of TNF-α activity is associated with significant reductions in REM sleep in abstinent alcohol-dependent patients. These data suggest that circulating levels of TNF-α may have a physiologic role in the regulation of REM sleep in humans.

a Cousins Center for Psychoneuroimmunology, University of California, Los Angeles, California

b The Scripps Research Institute, La Jolla, California

Corresponding Author InformationAddress reprint requests to Michael R. Irwin, M.D., Cousins Center for Psychoneuroimmunology, UCLA Semel Institute for Neuroscience, 300 UCLA Medical Plaza, Room 3130, Los Angeles, CA 90095-7076

PII: S0006-3223(08)01566-7

doi:10.1016/j.biopsych.2008.12.004


View previous. 19 of 20 View next.